High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers

Molecular Oncology

Volumn 7, Issue 6, 2013, Pages 1001-1011

  Grupp, Katharina ^a   Sanader, Stella ^a   Sirma, Hüseyin ^a   Simon, Ronald ^a   Koop, Christina ^a   Prien, Kristina ^a   Hube Magg, Claudia ^a   Salomon, Georg ^a   Graefen, Markus ^a   Heinzer, Hans ^a   Minner, Sarah ^a   Izbicki, Jakob R ^a   Sauter, Guido ^a   Schlomm, Thorsten ^a   Tsourlakis, Maria Christina ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

LPCAT1; Prostate cancer; Tissue microarray

Indexed keywords

1 ACYLGLYCEROPHOSPHOCHOLINE ACYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSCRIPTION FACTOR ERG;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CLINICAL DECISION MAKING; GLEASON SCORE; HUMAN; IMMUNOHISTOCHEMISTRY; LIPID METABOLISM; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; TISSUE MICROARRAY;

LPCAT1; PROSTATE CANCER; TISSUE MICROARRAY;

1-ACYLGLYCEROPHOSPHOCHOLINE O-ACYLTRANSFERASE; AGED; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPID METABOLISM; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84888003158     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.07.009     Document Type: Article

References (57)

1. Berger M.F., Lawrence M.S., Demichelis F., Drier Y., Cibulskis K., Sivachenko A.Y., Sboner A., Esgueva R., Pflueger D., Sougnez C., Onofrio R., Carter S.L., Park K., Habegger L., Ambrogio L., Fennell T., Parkin M., Saksena G., Voet D., Ramos A.H., Pugh T.J., Wilkinson J., Fisher S., Winckler W., Mahan S., Ardlie K., Baldwin J., Simons J.W., Kitabayashi N., MacDonald T.Y., Kantoff P.W., Chin L., Gabriel S.B., Gerstein M.B., Golub T.R., Meyerson M., Tewari A., Lander E.S., Getz G., Rubin M.A., Garraway L.A. The genomic complexity of primary human prostate cancer. Nature 2011, 470:214-220.
2. Brase J.C., Johannes M., Mannsperger H., Falth M., Metzger J., Kacprzyk L.A., Andrasiuk T., Gade S., Meister M., Sirma H., Sauter G., Simon R., Schlomm T., Beissbarth T., Korf U., Kuner R., Sultmann H. TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling. BMC Cancer 2011, 11:507.
3. Bridges J.P., Ikegami M., Brilli L.L., Chen X., Mason R.J., Shannon J.M. LPCAT1 regulates surfactant phospholipid synthesis and is required for transitioning to air breathing in mice. J.Clin. Invest. 2010, 120:1736-1748.
4. Burkhardt L., Fuchs S., Krohn A., Masser S., Mader M., Kluth M., Bachmann F., Huland H., Steuber T., Graefen M., Schlomm T., Minner S., Sauter G., Sirma H., Simon R. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res. 2013, 73:2795-2805.
5. Chen X., Hyatt B.A., Mucenski M.L., Mason R.J., Shannon J.M. Identification and characterization of a lysophosphatidylcholine acyltransferase in alveolar type II cells. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:11724-11729.
6. Cheng L., Han X., Shi Y. A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice. Am. J. Physiol. Endocrinol. Metab. 2009, 297:E1276-E1282.
7. Dobrzynska I., Szachowicz-Petelska B., Sulkowski S., Figaszewski Z. Changes in electric charge and phospholipids composition in human colorectal cancer cells. Mol. Cell Biochem. 2005, 276:113-119.
8. Dong Q., Patel M., Scott K.F., Graham G.G., Russell P.J., Sved P. Oncogenic action of phospholipase A2 in prostate cancer. Cancer Lett. 2006, 240:9-16.
9. El Gammal A.T., Bruchmann M., Zustin J., Isbarn H., Hellwinkel O.J., Kollermann J., Sauter G., Simon R., Wilczak W., Schwarz J., Bokemeyer C., Brummendorf T.H., Izbicki J.R., Yekebas E., Fisch M., Huland H., Graefen M., Schlomm T. Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. Clin. Cancer Res. 2010, 16:56-64.
10. Epstein J.I., Feng Z., Trock B.J., Pierorazio P.M. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur. Urol. 2012, 61:1019-1024.
11. Erbersdobler A., Fritz H., Schnoger S., Graefen M., Hammerer P., Huland H., Henke R.P. Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone. Eur. Urol. 2002, 41:40-46.
12. Faas F.H., Dang A.Q., Pollard M., Hong X.M., Fan K., Luckert P.H., Schutz M. Increased phospholipid fatty acid remodeling in human and rat prostatic adenocarcinoma tissues. J.Urol. 1996, 156:243-248.
13. Faas F.H., Dang A.Q., White J., Schaefer R., Johnson D. Increased prostatic lysophosphatidylcholine acyltransferase activity in human prostate cancer: a marker for malignancy. J.Urol. 2001, 165:463-468.
14. Flavin R., Peluso S., Nguyen P.L., Loda M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 2010, 6:551-562.
15. Freeman M.R., Yang W., Di Vizio D. Caveolin-1 and prostate cancer progression. Adv. Exp. Med. Biol. 2012, 729:95-110.
16. Furuta E., Okuda H., Kobayashi A., Watabe K. Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim. Biophys. Acta 2010, 1805:141-152.
17. Grupp K., Kohl S., Sirma H., Simon R., Steurer S., Becker A., Adam M., Izbicki J., Sauter G., Minner S., Schlomm T., Tsourlakis M.C. Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence. Mod. Pathol. 2013, 26:733-742.
18. Harayama T., Shindou H., Ogasawara R., Suwabe A., Shimizu T. Identification of a novel noninflammatory biosynthetic pathway of platelet-activating factor. J.Biol. Chem. 2008, 283:11097-11106.
19. Horie Y., Suzuki A., Kataoka E., Sasaki T., Hamada K., Sasaki J., Mizuno K., Hasegawa G., Kishimoto H., Iizuka M., Naito M., Enomoto K., Watanabe S., Mak T.W., Nakano T. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J.Clin. Invest. 2004, 113:1774-1783.
20. Il Lee S., Zuo X., Shureiqi I. 15-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: is the verdict in?. Cancer Metastasis Rev. 2011, 30:481-491.
21. Iljin K., Wolf M., Edgren H., Gupta S., Kilpinen S., Skotheim R.I., Peltola M., Smit F., Verhaegh G., Schalken J., Nees M., Kallioniemi O. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res. 2006, 66:10242-10246.
22. Jhavar S., Brewer D., Edwards S., Kote-Jarai Z., Attard G., Clark J., Flohr P., Christmas T., Thompson A., Parker M., Shepherd C., Stenman U.H., Marchbank T., Playford R.J., Woodhouse C., Ogden C., Fisher C., Kovacs G., Corbishley C., Jameson C., Norman A., De-Bono J., Bjartell A., Eeles R., Cooper C.S. Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU. Int. 2009, 103:1256-1269.
23. Kent C. Regulatory enzymes of phosphatidylcholine biosynthesis: a personal perspective. Biochim. Biophys. Acta 2005, 1733:53-66.
24. Klinger S.C., Glerup S., Raarup M.K., Mari M.C., Nyegaard M., Koster G., Prabakaran T., Nilsson S.K., Kjaergaard M.M., Bakke O., Nykjaer A., Olivecrona G., Petersen C.M., Nielsen M.S. SorLA regulates the activity of lipoprotein lipase by intracellular trafficking. J.Cell. Sci. 2011, 124:1095-1105.
25. Kluth M., Hesse J., Heinl A., Krohn A., Steurer S., Sirma H., Simon R., Mayer P.S., Schumacher U., Grupp K., Izbicki J.R., Pantel K., Dikomey E., Korbel J.O., Plass C., Sauter G., Schlomm T., Minner S. Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Mod. Pathol. 2013, 26:975-983.
26. Kohno M., Yokokawa K., Yasunari K., Minami M., Kano H., Hanehira T., Yoshikawa J. Induction by lysophosphatidylcholine, a major phospholipid component of atherogenic lipoproteins, of human coronary artery smooth muscle cell migration. Circulation 1998, 98:353-359.
27. Krohn A., Diedler T., Burkhardt L., Mayer P.S., De Silva C., Meyer-Kornblum M., Kotschau D., Tennstedt P., Huang J., Gerhauser C., Mader M., Kurtz S., Sirma H., Saad F., Steuber T., Graefen M., Plass C., Sauter G., Simon R., Minner S., Schlomm T. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am. J. Pathol. 2012, 181:401-412.
28. Kudo I., Murakami M. Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat. 2002, 68-69:3-58.
29. Lapointe J., Li C., Giacomini C.P., Salari K., Huang S., Wang P., Ferrari M., Hernandez-Boussard T., Brooks J.D., Pollack J.R. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res. 2007, 67:8504-8510.
30. Mansilla F., da Costa K.A., Wang S., Kruhoffer M., Lewin T.M., Orntoft T.F., Coleman R.A., Birkenkamp-Demtroder K. Lysophosphatidylcholine acyltransferase 1 (LPCAT1) overexpression in human colorectal cancer. J.Mol. Med. (Berl) 2009, 87:85-97.
31. Menendez J.A. Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: molecular mechanisms and therapeutic perspectives. Biochim. Biophys. Acta 2010, 1801:381-391.
32. Menendez J.A., Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 2007, 7:763-777.
33. Minner S., Enodien M., Sirma H., Luebke A.M., Krohn A., Mayer P.S., Simon R., Tennstedt P., Muller J., Scholz L., Brase J.C., Liu A.Y., Schluter H., Pantel K., Schumacher U., Bokemeyer C., Steuber T., Graefen M., Sauter G., Schlomm T. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin. Cancer Res. 2011, 17:5878-5888.
34. Minner S., Kraetzig F., Tachezy M., Kilic E., Graefen M., Wilczak W., Bokemeyer C., Huland H., Sauter G., Schlomm T. Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer. Hum. Pathol. 2011, 42:1946-1952.
35. Minner S., Wittmer C., Graefen M., Salomon G., Steuber T., Haese A., Huland H., Bokemeyer C., Yekebas E., Dierlamm J., Balabanov S., Kilic E., Wilczak W., Simon R., Sauter G., Schlomm T. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 2011, 71:281-288.
36. Mirlacher M., Simon R. Recipient block TMA technique. Methods Mol. Biol. 2010, 664:37-44.
37. Monet M., Gkika D., Lehen'kyi V., Pourtier A., Vanden Abeele F., Bidaux G., Juvin V., Rassendren F., Humez S., Prevarsakaya N. Lysophospholipids stimulate prostate cancer cell migration via TRPV2 channel activation. Biochim. Biophys. Acta 2009, 1793:528-539.
38. Morgan E.A., Forootan S.S., Adamson J., Foster C.S., Fujii H., Igarashi M., Beesley C., Smith P.H., Ke Y. Expression of cutaneous fatty acid-binding protein (C-FABP) in prostate cancer: potential prognostic marker and target for tumourigenicity-suppression. Int. J. Oncol. 2008, 32:767-775.
39. Muller J., Ehlers A., Burkhardt L., Sirma H., Steuber T., Graefen M., Sauter G., Minner S., Simon R., Schlomm T., Michl U. Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers. Int. J. Cancer 2013, 132:1333-1340.
40. Nakanishi H., Shindou H., Hishikawa D., Harayama T., Ogasawara R., Suwabe A., Taguchi R., Shimizu T. Cloning and characterization of mouse lung-type acyl-CoA:lysophosphatidylcholine acyltransferase 1 (LPCAT1). Expression in alveolar type II cells and possible involvement in surfactant production. J.Biol. Chem. 2006, 281:20140-20147.
41. Rubin M.A., Maher C.A., Chinnaiyan A.M. Common gene rearrangements in prostate cancer. J.Clin. Oncol. 2011, 29:3659-3668.
42. Santos C.R., Schulze A. Lipid metabolism in cancer. FEBS J. 2012, 279:2610-2623.
43. Schlomm T., Iwers L., Kirstein P., Jessen B., Kollermann J., Minner S., Passow-Drolet A., Mirlacher M., Milde-Langosch K., Graefen M., Haese A., Steuber T., Simon R., Huland H., Sauter G., Erbersdobler A. Clinical significance of p53 alterations in surgically treated prostate cancers. Mod. Pathol. 2008, 21:1371-1378.
44. Scott K.F., Sajinovic M., Hein J., Nixdorf S., Galettis P., Liauw W., de Souza P., Dong Q., Graham G.G., Russell P.J. Emerging roles for phospholipase A2 enzymes in cancer. Biochimie 2010, 92:601-610.
45. Shah U.S., Dhir R., Gollin S.M., Chandran U.R., Lewis D., Acquafondata M., Pflug B.R. Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma. Hum. Pathol. 2006, 37:401-409.
46. Shen G.M., Zhao Y.Z., Chen M.T., Zhang F.L., Liu X.L., Wang Y., Liu C.Z., Yu J., Zhang J.W. Hypoxia-inducible factor-1 (HIF-1) promotes LDL and VLDL uptake through inducing VLDLR under hypoxia. Biochem. J. 2012, 441:675-683.
47. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA. Cancer J. Clin. 2013, 63:11-30.
48. Suburu J., Chen Y.Q. Lipids and prostate cancer. Prostaglandins Other Lipid Mediat. 2012, 98:1-10.
49. Tamura K., Makino A., Hullin-Matsuda F., Kobayashi T., Furihata M., Chung S., Ashida S., Miki T., Fujioka T., Shuin T., Nakamura Y., Nakagawa H. Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism. Cancer Res. 2009, 69:8133-8140.
50. Taylor B.S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B.S., Arora V.K., Kaushik P., Cerami E., Reva B., Antipin Y., Mitsiades N., Landers T., Dolgalev I., Major J.E., Wilson M., Socci N.D., Lash A.E., Heguy A., Eastham J.A., Scher H.I., Reuter V.E., Scardino P.T., Sander C., Sawyers C.L., Gerald W.L. Integrative genomic profilingof human prostate cancer. Cancer Cell 2010, 18:11-22.
51. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., Varambally S., Cao X., Tchinda J., Kuefer R., Lee C., Montie J.E., Shah R.B., Pienta K.J., Rubin M.A., Chinnaiyan A.M. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
52. Vainio P., Gupta S., Ketola K., Mirtti T., Mpindi J.P., Kohonen P., Fey V., Perala M., Smit F., Verhaegh G., Schalken J., Alanen K.A., Kallioniemi O., Iljin K. Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer. Am. J. Pathol. 2011, 178:525-536.
53. Vainio P., Lehtinen L., Mirtti T., Hilvo M., Seppanen-Laakso T., Virtanen J., Sankila A., Nordling S., Lundin J., Rannikko A., Oresic M., Kallioniemi O., Iljin K. Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins. Oncotarget 2011, 2:1176-1190.
54. Verschoor M.L., Wilson L.A., Verschoor C.P., Singh G. Ets-1 regulates energy metabolism in cancer cells. PloS One 2010, 5:e13565.
55. Zeisig R., Koklic T., Wiesner B., Fichtner I., Sentjurc M. Increase in fluidity in the membrane of MT3 breast cancer cells correlates with enhanced cell adhesion invitro and increased lung metastasis in NOD/SCID mice. Arch. Biochem. Biophys. 2007, 459:98-106.
56. Zellweger T., Gunther S., Zlobec I., Savic S., Sauter G., Moch H., Mattarelli G., Eichenberger T., Curschellas E., Rufenacht H., Bachmann A., Gasser T.C., Mihatsch M.J., Bubendorf L. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. Int. J. Cancer 2009, 124:2116-2123.
57. Zhou X., Lawrence T.J., He Z., Pound C.R., Mao J., Bigler S.A. The expression level of lysophosphatidylcholine acyltransferase 1 (LPCAT1) correlates to the progression of prostate cancer. Exp. Mol. Pathol. 2012, 92:105-110.